🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Porton Pharma Solutions Ltd. (SHE:300363)
China flag China · Delayed Price · Currency is CNY
20.18
-0.84 (-4.00%)
Nov 20, 2026, 3:04 PM CST

Porton Pharma Solutions Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
3,6173,3972,9893,6587,0083,074
Other Revenue
22.9822.9823.119.4426.9931.17
3,6403,4203,0123,6677,0353,105
Revenue Growth
6.09%13.54%-17.87%-47.87%126.55%49.87%
Cost of Revenue
2,4522,4242,3092,2303,3981,843
Gross Profit
1,188995.37702.621,4373,6361,262
Selling, General & Admin
624559.38557.81693.17807.66386.63
Research & Development
234.68267.58338.49452.23519.51262.02
Other Operating Expenses
56.322.110.0535.0958.5414.06
Operating Expenses
931.48867.27926.631,1451,419706.17
Operating Income
256.87128.11-224291.882,218555.88
Interest Expense
-36.47-50.48-62.06-44.15-27.73-21.7
Interest & Investment Income
19.059.0724.0857.8822.8314.31
Currency Exchange Gain (Loss)
-24.31-24.3110.11-20.0150.2510.79
Other Non Operating Income (Expenses)
11.54-1.37-1.64-2.53-6.73-1.5
EBT Excluding Unusual Items
226.6961.02-253.5283.072,256557.77
Impairment of Goodwill
----40.64--
Gain (Loss) on Sale of Investments
1.66.52-49.24-1.63-8.18-6.79
Gain (Loss) on Sale of Assets
-2.01-1.17-0.770.540.1-3.21
Asset Writedown
-343.68-22.8-92.57-17.49-18.63-16.22
Other Unusual Items
36.4839.1122.0422.7116.2817.28
Pretax Income
-80.9182.68-374.05246.562,246548.83
Income Tax Expense
70.3252.29-8.0671.05309.3873.24
Earnings From Continuing Operations
-151.2330.39-365.99175.521,936475.59
Minority Interest in Earnings
55.5165.9578.2491.3468.9948.33
Net Income
-95.7296.34-287.75266.862,005523.92
Net Income to Common
-95.7296.34-287.75266.862,005523.92
Net Income Growth
----86.69%282.78%61.49%
Shares Outstanding (Basic)
536535543545542540
Shares Outstanding (Diluted)
536535543545543540
Shares Change
0.20%-1.42%-0.31%0.21%0.62%-0.11%
EPS (Basic)
-0.180.18-0.530.493.700.97
EPS (Diluted)
-0.180.18-0.530.493.690.97
EPS Growth
----86.72%280.41%61.67%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
727.11464.45-85.06-500.811,391-296.8
Free Cash Flow Per Share
1.360.87-0.16-0.922.56-0.55
Dividend Per Share
0.0900.090-0.4871.1060.193
Dividend Growth
----55.97%473.06%59.50%
Gross Margin
32.65%29.11%23.33%39.19%51.69%40.64%
Operating Margin
7.06%3.75%-7.44%7.96%31.52%17.90%
Profit Margin
-2.63%2.82%-9.55%7.28%28.51%16.87%
Free Cash Flow Margin
19.98%13.58%-2.82%-13.66%19.78%-9.56%
EBITDA
628.81480.28101.8580.682,452719.86
EBITDA Margin
17.27%14.04%3.38%15.83%34.86%23.18%
D&A For EBITDA
371.94352.17325.8288.8234.54163.98
EBIT
256.87128.11-224291.882,218555.88
EBIT Margin
7.06%3.75%-7.44%7.96%31.52%17.90%
Effective Tax Rate
-63.24%-28.81%13.78%13.35%
Revenue as Reported
3,6403,4203,0123,6677,0353,105